12,145 followers
RT @FrontOncology: New research: Immunotherapy utilization in stage IIIA melanoma: less may be more: Background Immunotherapy agents are a…
RT @FrontOncology: New research: Immunotherapy utilization in stage IIIA melanoma: less may be more: Background Immunotherapy agents are a…
New research: Immunotherapy utilization in stage IIIA melanoma: less may be more: Background Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is… https://t.co